210 related articles for article (PubMed ID: 34329579)
21. Progressive multifocal leukoencephalopathy and rheumatoid arthritis treatments.
Clavel G; Moulignier A; Semerano L
Joint Bone Spine; 2017 Dec; 84(6):671-675. PubMed ID: 28323224
[TBL] [Abstract][Full Text] [Related]
22. Progressive multifocal leukoencephalopathy in chronic lymphocytic leukemia: a report of three cases and review of the literature.
D'Souza A; Wilson J; Mukherjee S; Jaiyesimi I
Clin Lymphoma Myeloma Leuk; 2010 Feb; 10(1):E1-9. PubMed ID: 20223720
[TBL] [Abstract][Full Text] [Related]
23. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis.
Fleischmann RM
Arthritis Rheum; 2009 Nov; 60(11):3225-8. PubMed ID: 19877057
[TBL] [Abstract][Full Text] [Related]
24. Changes in the natural history of progressive multifocal leukoencephalopathy in HIV-negative lymphoproliferative disorders: impact of novel therapies.
García-Suárez J; de Miguel D; Krsnik I; Bañas H; Arribas I; Burgaleta C
Am J Hematol; 2005 Dec; 80(4):271-81. PubMed ID: 16315252
[TBL] [Abstract][Full Text] [Related]
25. Progressive Multifocal Leukoencephalopathy Following Combined Rituximab-Based Immune-Chemotherapy for Post-transplant Lymphoproliferative Disorder in a Renal Transplant Recipient: A Case Report.
Windpessl M; Burgstaller S; Kronbichler A; Pieringer H; Kalev O; Karrer A; Wallner M; Thaler J
Transplant Proc; 2018 Apr; 50(3):881-883. PubMed ID: 29661457
[TBL] [Abstract][Full Text] [Related]
26. Progressive Multifocal Leukoencephalopathy in Primary Immunodeficiencies.
Hadjadj J; Guffroy A; Delavaud C; Taieb G; Meyts I; Fresard A; Streichenberger N; L'Honneur AS; Rozenberg F; D'Aveni M; Aguilar C; Rosain J; Picard C; Mahlaoui N; Lecuit M; Hermine O; Lortholary O; Suarez F
J Clin Immunol; 2019 Jan; 39(1):55-64. PubMed ID: 30552536
[TBL] [Abstract][Full Text] [Related]
27. A Chronic Lymphocytic Leukemia Patient with Progressive Multifocal Leukoencephalopathy Caused by John Cunningham Virus.
Ramadhani P; Bramantono B; Sedana MP
Acta Med Indones; 2018 Apr; 50(2):151-158. PubMed ID: 29950535
[TBL] [Abstract][Full Text] [Related]
28. Progressive multifocal leukoencephalopathy associated with immunosuppressive therapy in rheumatic diseases: evolving role of biologic therapies.
Molloy ES; Calabrese LH
Arthritis Rheum; 2012 Sep; 64(9):3043-51. PubMed ID: 22422012
[TBL] [Abstract][Full Text] [Related]
29. Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.
Martin Mdel P; Cravens PD; Winger R; Kieseier BC; Cepok S; Eagar TN; Zamvil SS; Weber MS; Frohman EM; Kleinschmidt-Demasters BK; Montine TJ; Hemmer B; Marra CM; Stüve O
Arch Neurol; 2009 Aug; 66(8):1016-20. PubMed ID: 19667224
[TBL] [Abstract][Full Text] [Related]
30. Progressive multifocal leukoencephalopathy in autoimmune diseases.
Palazzo E; Yahia SA
Joint Bone Spine; 2012 Jul; 79(4):351-5. PubMed ID: 22281228
[TBL] [Abstract][Full Text] [Related]
31. Infratentorial progressive multifocal leukoencephalopathy in a patient treated with fludarabine and rituximab.
Bonavita S; Conforti R; Russo A; Sacco R; Tessitore A; Gallo A; Della Corte M; Monsurrò MR; Tedeschi G
Neurol Sci; 2008 Feb; 29(1):37-9. PubMed ID: 18379739
[TBL] [Abstract][Full Text] [Related]
32. Drug-induced progressive multifocal leukoencephalopathy: Lessons learned from contrasting natalizumab and rituximab.
Vermeer NS; Straus SM; Mantel-Teeuwisse AK; Hidalgo-Simon A; Egberts AC; Leufkens HG; De Bruin ML
Clin Pharmacol Ther; 2015 Nov; 98(5):542-50. PubMed ID: 26347128
[TBL] [Abstract][Full Text] [Related]
33. Progressive multifocal leukoencephalopathy and reversible progressive leukoencephalopathy syndrome in dermatologic therapy.
Ladizinski B; Heller MM; Bhutani T; Zitelli KB; Koo JY
J Drugs Dermatol; 2013 Feb; 12(2):e20-4. PubMed ID: 23377400
[TBL] [Abstract][Full Text] [Related]
34. Drug-induced progressive multifocal leukoencephalopathy: a case/noncase study in the French pharmacovigilance database.
Colin O; Favrelière S; Quillet A; Neau JP; Houeto JL; Lafay-Chebassier C; Pérault-Pochat MC;
Fundam Clin Pharmacol; 2017 Apr; 31(2):237-244. PubMed ID: 27736027
[TBL] [Abstract][Full Text] [Related]
35. A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy.
Chahin S; Berger JR
J Neurovirol; 2015 Dec; 21(6):623-31. PubMed ID: 25404234
[TBL] [Abstract][Full Text] [Related]
36. Considerations on the appropriateness of the John Cunningham virus antibody assay use in patients with rheumatoid arthritis.
Borie D; Kremer JM
Semin Arthritis Rheum; 2015 Oct; 45(2):163-6. PubMed ID: 26190565
[TBL] [Abstract][Full Text] [Related]
37. The Incidence and Predisposing Factors of John Cunningham Virus-Induced Progressive Multifocal Leukoencephalopathy in Southern Finland: A Population-Based Study.
Kartau M; Verkkoniemi-Ahola A; Paetau A; Palomäki M; Janes R; Ristola M; Lappalainen M; Anttila VJ
Open Forum Infect Dis; 2019 Feb; 6(2):ofz024. PubMed ID: 30815501
[TBL] [Abstract][Full Text] [Related]
38. Rapid cognitive decline in a patient with chronic lymphocytic leukaemia: a case report.
Forryan J; Yong J
J Med Case Rep; 2020 Mar; 14(1):39. PubMed ID: 32127027
[TBL] [Abstract][Full Text] [Related]
39. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA's adverse event reporting system.
Raisch DW; Rafi JA; Chen C; Bennett CL
Expert Opin Drug Saf; 2016 Aug; 15(8):1003-11. PubMed ID: 27268272
[TBL] [Abstract][Full Text] [Related]
40. The Risk of Progressive Multifocal Leukoencephalopathy in the Biologic Era: Prevention and Management.
Molloy ES; Calabrese CM; Calabrese LH
Rheum Dis Clin North Am; 2017 Feb; 43(1):95-109. PubMed ID: 27890176
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
